IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Stopped early · Phase 2

Conditions studied: Von Willebrand Disease

In brief

The purpose of this study is to determine the efficacy and safety of rhIL-11 when given subcutaneously in adults with type 1 von Willebrand disease undergoing elective surgery or major dental procedure. Efficacy will be measured by estimated blood loss, and frequency and severity of bleeding and transfusion requirement during and after surgery. Safety will be measured by the frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema.

Key facts

Study ID

NCT00524225

Run by

Margaret Ragni

People needed

3

Starts

2008-02-01

Expected to finish

2012-06-01

Last updated by the study team

2019-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females 18 years of age and older
• Confirmed type 1 VWD, as defined by low VWF:RCoF or low VWF:Ag and qualitatively normal VWF multimers
• A past bleeding history
• Responsive to DDAVP
• Scheduled elective major surgery or major dental surgery at MUH or PUH
• Willingness to have blood drawn

You may not qualify if…

• Presence of other bleeding disorders, acquired Von Willebrand disease, primary thrombocytopenia
• Use of immunomodulatory or experimental drugs, or diuretics
• Pregnant or lactating women or those unwilling to use contraception during study
• Previous cardiac disease, congestive failure, arrhythmia (e.g. atrial fibrillation, atrial flutter), hypertension, MI, stroke, or thrombosis
• Past allergic reaction to Neumega or DDAVP
• Surgery within the past 8 weeks
• Inability to comply with study protocol requirements
• Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs
• Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study
• Past allergic reaction to Neumega or DDAVP
• Surgery within the past 8 weeks
• Inability to comply with study protocol requirements
• Concomitant use of antiplatelet drugs, anticoagulants, dextran, aspirin or NSAIDs
• Treatment with DDAVP, cryoprecipitate, whole blood, plasma and plasma derivatives containing substantial quantities of FVIII and/or VWF within five days of study

Where it is running

• Hemophilia Center of Western PA — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.